Back to Newsroom

Debiopharm Diagnostics Portfolio Company Biocartis Ships its First Idylla Instrument

Lausanne, Switzerland – September 17, 2014 – Debiopharm Diagnostics, part of Debiopharm Group, is proud to congratulate Biocartis commitment in shipping its first Idylla instrument. Debiopharm Diagnostics is a long-time investor in Biocartis as part of Debiopharm Diagnostics’ portfolio.

Idylla™, Biocartis’ fully automated, real-time PCR based molecular diagnostics system, is designed to offer physicians fast and easy access to clinical molecular diagnostic information, anywhere and anytime. Idylla opens the door to near-patient molecular testing, moving this essential diagnostic out of the central laboratory and nearer to the point of care, offering a great improvement in rapidity and quality of actionable results.

Click here to read more